Investor Library

StemRIMIR Library

All Timely Disclosure Information Financial Results Presentation Materials IR News

July 13, 2026	Timely Disclosure Information	StemRIM Announces Patent Registration (Canada) for Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy, Old Myocardial Infarction
July 8, 2026	Timely Disclosure Information	StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (SR-GT1) Aimed at Curative Treatment of DEB in ,South Korea
July 6, 2026	IR News	StemRIM Announces Publication of a Paper on Novel Finding about Contribution of Ectomesenchyme for Epidermal Stem Cell Formation
June 17, 2026	Timely Disclosure Information	StemRIM Announces Patent Registration (Australia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
June 16, 2026	Timely Disclosure Information	StemRIM Announces Patent Registration (Russia) for Redasemtide, as a Therapeutic Indication for Fatty Liver and Non-alcoholic Steatohepatitis
June 10, 2026	Timely Disclosure Information	Non-consolidated Financial Results for the Nine Months Ended April 30, 2026 [Japanese GAAP]
May 15, 2026	IR News	StemRIM Announces Publication of a Paper on a Physician-Initiated Phase 2 Clinical Trial of Redasemtide (HMGB1 Peptide) for Chronic Liver Disease
May 13, 2026	Timely Disclosure Information	StemRIM Announces Setting the Record Date and Holding for Extraordinary General Meeting of Shareholders and Reduction of Capital Stock
May 12, 2026	Timely Disclosure Information	StemRIM Announces the Progress for Regeneration-Inducing Medicine Redasemtide
April 15, 2026	Timely Disclosure Information	StemRIM Announces Completion of Patient Enrollment in the Phase 1,2 Clinical Trial of Redasemtide for Patients with Ischemic Cardiomyopathy
April 7, 2026	IR News	StemRIM Inc. is featured on an international public relations video produced by the Public Relations Office, Cabinet Office.
March 13, 2026	Timely Disclosure Information	Presentation Material Financial Results for the Six Months Ended January 31, 2026
March 11, 2026	Timely Disclosure Information	Non-consolidated Financial Results for the Six Months Ended January 31, 2026 [Japanese GAAP]
March 2, 2026	Timely Disclosure Information	StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (Development Code: SR-GT1) Aimed at Curative Treatment of DEB
February 17, 2026	Timely Disclosure Information	StemRIM Announces Patent Registration (Canada) for the Use of Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders